Actos (Pioglitazone) in Children Under 12: What the Evidence Says About Off-Label Use

Why Pioglitazone Is Used Off-Label in Young Children

Pioglitazone belongs to the thiazolidinedione class. It activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), which improves insulin sensitivity in adipose tissue, skeletal muscle, and liver. The FDA approved it for adult type 2 diabetes management in 1999, but that approval has never been extended below age 18 [1].

Clinicians occasionally consider pioglitazone in children under 12 when other options have failed or are not tolerated. Conditions that generate these conversations include severe insulin resistance syndromes, nonalcoholic fatty liver disease (NAFLD) with metabolic underpinning, and type 2 diabetes presenting in early childhood, a presentation that, while uncommon, is rising alongside pediatric obesity rates.

The Regulatory Gap

The FDA label for pioglitazone (Actos) states explicitly that safety and efficacy have not been established in pediatric patients [1]. The Pediatric Research Equity Act requires sponsors to study drugs in children, but Takeda, the original manufacturer, was not compelled to complete pediatric studies that met the threshold for a labeled indication in the under-12 group. This leaves clinicians without a dosing table, a safety database, or any approved prescribing guidance for this cohort.

Rising Pediatric Metabolic Disease as Context

The CDC estimates that approximately 19.7% of U.S. Children ages 2 to 19 have obesity [2]. Rates of pediatric type 2 diabetes and nonalcoholic fatty liver disease follow closely behind those obesity trends. With metformin as the only FDA-approved oral antidiabetic agent for children as young as 10, and with insulin as the other guideline-endorsed option for younger children with type 2 diabetes, the practical toolkit is thin [3]. That gap drives some prescribers toward TZDs in select cases.

What the Clinical Evidence Shows

The evidence base for pioglitazone in patients under 12 is sparse. Most published data involve patients in the 10-to-17 age range, with very few studies focused specifically on children under 12. Interpreting that evidence requires honesty about what the data can and cannot support.

Insulin Resistance and Glycemic Control

A 24-week open-label pilot by Zeitler et al. Enrolled adolescents aged 10 to 17 with type 2 diabetes and tested pioglitazone 15 to 45 mg daily. HbA1c fell by a mean of 0.8 percentage points in the pioglitazone arm, and fasting insulin dropped by roughly 30% from baseline [4]. The study was not powered for superiority, and the cohort skewed older (mean age 14.2 years), so direct extrapolation to children under 12 is limited.

The TODAY trial, the largest randomized controlled study of pediatric type 2 diabetes management (N=699, ages 10 to 17), compared metformin alone, metformin plus rosiglitazone (a different TZD), and metformin plus an intensive lifestyle program [5]. Metformin plus rosiglitazone showed a statistically significant reduction in treatment failure compared to metformin alone (38.6% vs. 51.7%, P<0.001) [5]. Pioglitazone was not one of the study arms, but these results inform the biological plausibility of TZD benefit in this age range, and they remain the highest-quality pediatric TZD dataset available.

NAFLD and Liver Outcomes

Nonalcoholic steatohepatitis (NASH) in children shares many of the insulin-resistance mechanisms targeted by pioglitazone. A 2006 pilot trial by Lavine et al. (N=10, ages 9 to 17) found that pioglitazone 30 mg daily for 24 weeks produced a 40% mean reduction in ALT from baseline [6]. Liver biopsy data in that study suggested histologic improvement in two of five patients who underwent repeat biopsy. The sample size prevents any definitive claim, but the ALT signal was consistent enough to motivate larger follow-on work.

The larger TONIC trial (N=173, ages 8 to 17) tested metformin, vitamin E, and placebo for pediatric NAFLD [7]. Pioglitazone was not an arm, but TONIC established that pediatric NAFLD responds to metabolic interventions, a relevant background finding. Vitamin E showed a statistically significant improvement in NASH resolution at 96 weeks compared to placebo (P<0.05), while metformin did not meet the primary endpoint [7].

Severe Insulin Resistance Syndromes

Case series describe pioglitazone use in children with lipodystrophy, polycystic ovarian syndrome, and type A insulin resistance syndromes, some as young as 8 years old [8]. These reports consistently show improvement in fasting insulin, triglycerides, and hepatic fat fraction on MRI. They do not show consistent effects on growth, pubertal staging, or long-term cardiovascular outcomes in this young cohort.

Dosing Considerations for Children Under 12

No approved pediatric dosing table exists. Prescribers who use pioglitazone off-label in this age group typically start at 15 mg once daily, the same starting dose used in adult trials, and titrate cautiously based on tolerability and response.

Weight-Based Reasoning

Adult dosing ranges from 15 to 45 mg daily. A child under 12 may weigh 20 to 40 kg, meaning a 15 mg dose represents a substantially higher mg/kg exposure than the same dose in a 90 kg adult. Some pediatric endocrinologists apply a 0.2 to 0.5 mg/kg/day starting range, though this approach is not validated in prospective trials [4]. Pharmacy compounding is sometimes used to achieve lower doses, which introduces its own variability in drug delivery.

Duration of Treatment

In adult NASH trials, pioglitazone has been studied over periods as long as 36 months. Pediatric studies have generally run 24 weeks. No data exist on what duration is safe or necessary in the under-12 group, and no data exist on what happens to bone density, body composition, or insulin sensitivity after treatment is stopped in young children.

Monitoring Protocol

Prescribers using pioglitazone off-label in children should obtain the following at baseline and on a schedule consistent with pediatric endocrinology practice:

• Fasting glucose and HbA1c every 3 months
• Liver function tests (ALT, AST) at baseline, 8 weeks, and every 3 months thereafter
• Body weight and BMI at every visit
• Blood pressure and signs of fluid retention at every visit
• Bone-density assessment (DXA) at baseline for children at elevated fracture risk, with repeat scanning at 12 months

The FDA label for adult patients warns that pioglitazone may cause fluid retention, which can exacerbate or precipitate heart failure. This risk is not quantified in children, but the mechanism is the same.

Safety Profile: Specific Risks in the Under-12 Population

Pioglitazone's safety concerns in adults are well-documented. Translating those concerns to a child under 12 requires additional caution because the developing skeleton, the hormonal environment of prepubescence, and the longer expected treatment horizon all modify the risk profile.

Weight Gain

In adult randomized trials, pioglitazone produces mean weight gains of 2 to 5 kg over 6 to 12 months, primarily from fluid retention and increased adipose mass [9]. In children already carrying excess adiposity, this is a meaningful concern. The TODAY trial found that rosiglitazone (a closely related TZD) produced 3.2 kg more weight gain at 24 months compared to metformin alone in adolescents [5]. Children under 12 may be more sensitive to these effects due to differences in fat distribution regulation during prepubescence.

Bone Density

A 2015 meta-analysis of adult TZD trials (N=10,680 patients across 12 randomized studies) found that TZD use was associated with a significant reduction in bone mineral density and an increased fracture risk in women (relative risk 1.57, 95% CI 1.26 to 1.95) [10]. Skeletal effects in adult men were smaller but present. Bone accrual is at its peak rate in children ages 8 to 12, meaning any TZD-related interference with PPAR-gamma signaling in osteoblasts during this window could have consequences that persist decades beyond treatment. No pediatric study has adequately quantified this risk.

Bladder Cancer Signal

The FDA issued a warning in 2011 regarding a possible increased risk of bladder cancer with more than 12 months of pioglitazone use in adults, based on a 10-year interim analysis of the Kaiser Permanente cohort [11]. The absolute risk increase was small (approximately 3 additional cases per 10,000 person-years), and subsequent meta-analyses have produced conflicting results. In children, where cumulative drug exposure could extend over many decades if use begins young, this signal warrants explicit discussion with families even if the absolute risk remains uncertain.

Fluid Retention and Cardiac Effects

Pioglitazone causes sodium and water retention through renal tubular mechanisms. Children with subclinical cardiomyopathy, those receiving concomitant insulin, or those with renal insufficiency face a higher risk of clinically significant fluid overload. Any child prescribed pioglitazone should have a baseline echocardiogram if cardiac history or symptoms suggest elevated risk, consistent with general pediatric endocrinology practice [12].

Regulatory and Guideline Positions

The major diabetes and pediatric endocrinology organizations have not endorsed pioglitazone for use in children under 12. Their current stances are as follows.

American Diabetes Association (ADA)

The ADA's 2024 Standards of Care state that metformin and insulin remain the only FDA-approved pharmacologic options for type 2 diabetes management in children and adolescents, and note that "the evidence base for other glucose-lowering agents in youth is limited" [3]. The ADA Standards do not provide a specific recommendation for or against off-label TZD use in children under 12, but they do not list it as an acceptable alternative to approved options.

International Society for Pediatric and Adolescent Diabetes (ISPAD)

ISPAD guidelines published in 2022 acknowledge that some clinicians use TZDs in pediatric patients with severe insulin resistance syndromes, but stop short of recommending routine use and note the absence of long-term pediatric safety data [13]. The guidelines specifically state that "thiazolidinediones are not currently recommended as standard therapy in youth with type 2 diabetes."

FDA Label Status

The current FDA-approved prescribing information for pioglitazone (Actos) includes the following language under Pediatric Use: "Safety and effectiveness in pediatric patients have not been established" [1]. This language has not changed since the drug's approval and reflects the absence of adequate and well-controlled trials in this population.

Clinical Decision Framework: When Might Off-Label Use Be Considered?

Off-label pioglitazone in a child under 12 is not a first-line, second-line, or even third-line decision for most prescribers. The following framework reflects the conditions under which a pediatric endocrinologist might, and might not, consider it, based on the current evidence and guideline context.

Consider a specialist consultation (not pioglitazone directly) when a child under 12 presents with:

• Fasting insulin above 30 mIU/L with acanthosis nigricans and BMI above the 97th percentile, after 3 to 6 months of structured lifestyle intervention
• NAFLD confirmed on ultrasound or MRI with ALT persistently above two times the upper limit of normal, after ruling out other etiologies
• A diagnosed lipodystrophy syndrome or type A insulin resistance syndrome with inadequate response to metformin

Consider pioglitazone only after all of the following are met:

1. Metformin has been trialed at maximum tolerated dose for at least 3 months without adequate response
2. Insulin resistance is confirmed biochemically, not assumed from BMI alone
3. A pediatric cardiologist has cleared the child for fluid-retention risk
4. Parents or guardians have received documented informed consent covering weight gain, bone-density uncertainty, the bladder-cancer signal, and the absence of pediatric approval
5. A DXA baseline scan has been obtained
6. The prescribing physician has subspecialty training in pediatric endocrinology or is working directly under one

Do not use pioglitazone in children under 12 with any of the following: active or suspected liver disease (ALT above three times upper limit of normal), known or suspected heart failure, current insulin therapy without close monitoring infrastructure, or a family or personal history of bladder cancer.

Comparing Pioglitazone to Other Off-Label Options in This Age Group

Pioglitazone is not the only off-label metabolic agent used in young children. Comparing it to alternatives helps contextualize its risk-benefit position.

Metformin (Ages 10 and Up, FDA-Approved)

Metformin is approved for children as young as 10 with type 2 diabetes. For children under 10, it is itself off-label, but it carries a vastly larger pediatric safety database, no weight-gain signal, and no bone-density concern [3]. It remains the standard comparator against which pioglitazone must be measured.

GLP-1 Receptor Agonists

Liraglutide received FDA approval in 2019 for adolescents aged 10 and older with type 2 diabetes (Victoza 1.8 mg daily), and semaglutide (Ozempic) received approval for adolescents 12 and older in 2022 [14]. For children strictly under 12, GLP-1 agents are also off-label, but they carry weight-loss rather than weight-gain profiles, making them mechanistically attractive in the obese pediatric patient. Head-to-head data against pioglitazone in children under 12 do not exist.

Vitamin E for NAFLD

The TONIC trial showed that vitamin E 800 IU daily produced histologic NASH resolution in children at a rate of 58% versus 28% for placebo (P<0.05) [7]. Vitamin E carries a much simpler safety profile than pioglitazone in this context. Many pediatric hepatologists use vitamin E as the first pharmacologic step in pediatric NAFLD before considering any insulin sensitizer, including pioglitazone.

What Families Should Know Before Agreeing to Off-Label Use

Families who are presented with a pioglitazone prescription for a child under 12 should ask specific questions before agreeing. The following list reflects reasonable due diligence for any off-label prescribing in a pediatric patient:

• What approved alternatives have been tried and why did they fail?
• What specific outcome are we measuring, and at what time point will we reassess?
• What is the plan if the child gains more than 5% of body weight on this medication?
• Has a bone-density baseline scan been scheduled?
• What is the stopping criteria, and how long is the planned treatment course?
• Will a pediatric endocrinologist be co-managing this prescription?

Prescribers should document that these questions were addressed. Off-label prescribing is legal and sometimes clinically appropriate, but the informed-consent standard is higher when the patient is a minor and the drug lacks any pediatric approval.

Practical Monitoring Table for Clinicians

| Parameter | Baseline | 4 Weeks | 8 Weeks | Every 3 Months | |---|---|---|---|---| | HbA1c | Yes | No | No | Yes | | Fasting glucose | Yes | Yes | Yes | Yes | | ALT / AST | Yes | No | Yes | Yes | | Body weight / BMI | Yes | Yes | Yes | Yes | | Blood pressure | Yes | Yes | Yes | Yes | | Fluid retention signs | Yes | Yes | Yes | Yes | | DXA (bone density) | Yes (if at risk) | No | No | At 12 months | | Echocardiogram | Yes (if cardiac Hx) | No | No | As indicated |